Dialysis modality and mortality in polycystic kidney disease

Zhou, Chenchen; Gu, Yaodong; Mei, Changlin; Dai, Bing; Wang, Yi; Xue, Cheng

doi:10.1111/hdi.12673

Cited by 8 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, another study reports that dialysis modality is not associated with the mortality rate in patients with heart failure 56 . One meta‐analysis reports a similar mortality rate between patients undergoing hemodialysis and patients undergoing peritoneal dialysis 57 . To determine the potency of IL‐6 measurement in patients who received different dialysis modalities, subgroup analyses were performed.…”

Section: Discussionmentioning

confidence: 99%

“… 56 One meta‐analysis reports a similar mortality rate between patients undergoing hemodialysis and patients undergoing peritoneal dialysis. 57 To determine the potency of IL‐6 measurement in patients who received different dialysis modalities, subgroup analyses were performed. The findings indicated that IL‐6 could estimate both cardiovascular risk and all‐cause mortality risk in hemodialysis patients and mixed type dialysis patients but not in peritoneal dialysis patients (IL‐6 was a nonsignificant predictor of mortality risk in peritoneal dialysis patients).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Interleukin‐6 levels can be used to estimate cardiovascular and all‐cause mortality risk in dialysis patients: A meta‐analysis and a systematic review

Chen

Wang

2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background Although previous studies have explored the correlation of interleukin (IL)−6 with mortality risk in dialysis patients, the findings have been conflicting. Hence, this meta‐analysis aimed to comprehensively assess the use of IL‐6 measurement for estimating cardiovascular mortality and all‐cause mortality in dialysis patients. Methods The Embase, PubMed, Web of Science, and MEDLINE databases were searched to identify relevant studies. After screening out the eligible studies, the data were extracted. Results Twenty‐eight eligible studies with 8370 dialysis patients were included. Pooled analyses revealed that higher IL‐6 levels were related to increased cardiovascular mortality risk (hazard ratio [HR] = 1.55, 95% confidence interval [CI]: 1.20–1.90) and all‐cause mortality risk (HR = 1.11, 95% CI: 1.05–1.17) in dialysis patients. Further subgroup analyses suggested that higher IL‐6 levels were associated with elevated cardiovascular mortality in hemodialysis patients (HR = 1.59, 95% CI: 1.36–1.81) but not in peritoneal dialysis patients (HR = 1.56, 95% CI: 0.46–2.67). Moreover, sensitivity analyses indicated that the results were robust. Egger's test revealed potential publication bias among studies exploring the correlation of IL‐6 levels with cardiovascular mortality (p = .004) and all‐cause mortality (p < .001); however, publication bias was not observed when using Begg's test (both p > .05). Conclusions This meta‐analysis reveals that higher IL‐6 levels could indicate higher risks of cardiovascular mortality and all‐cause mortality in dialysis patients. These findings suggest that monitoring IL‐6 cytokine may help to enhance dialysis management and improve the general prognosis of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Interleukin‐6 levels can be used to estimate cardiovascular and all‐cause mortality risk in dialysis patients: A meta‐analysis and a systematic review

Chen

Wang

2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

show abstract

“…Rappelons enfin que deux autres méta-analyses récentes [13,14], regroupant plus de 7500 patients PKAD, se sont intéressées à comparer la mortalité des patients pris en charge en DP et en hémodialyse. Il s'avère que la mortalité ne diffère pas entre les deux techniques de dialyse.…”

Section: Discussionunclassified

Patients’ outcome with polycystic kidney disease firstly treated with peritoneal dialysis. Experience of our home dialysis unit since 1997.

Poux

Cardozo²,

Laville³

et al. 2021

Bull Dial Domic

View full text Add to dashboard Cite

We extracted data from the French Speaking Registry of Peritoneal Dialysis and retrospectively studied peritonitis and the outcome of 30 patients with polycystic kidney disease firstly treated with peritoneal dialysis within our dialysis unit since 1997. There were 15 men and 15 women with a mean age of 54 years. Eighty-five per-cent of the patients had hepatic impairment. Ten patients did not suffer from comorbidities. Charlson comorbidity index was greater than or equal to 4 in five patients. Most of the patients was treated with automated peritoneal dialysis during the night. Only one patient was not autonomous with peritoneal dialysis. The whole medical monitoring lasted 836 months, representing an average of 28 months per patient. Eleven patients had a total of 24 peritonitis, 9 with gram negative bacillus. The incidence of peritonitis was one episode every 35 months-patient. Peritonitis was responsible for sudden admission in hemodialysis unit in two cases and death in one case. Fifteen patients (50%) benefited from renal transplantation. Only one patient had to undergo nephrectomy prior to renal transplantation. Seven patients were admitted to hemodialysis unit (the median duration time on peritoneal dialysis was 36 months). Four patients died. Four patients are currently treated with peritoneal dialysis. In conclusion, this retrospective study points out that peritoneal dialysis, especially automated peritoneal dialysis, is a good option for patients with polycystic kidney disease necessitating dialysis.

show abstract

“…However, whether PD is a feasible option for patients with ADPKD remains controversial due to inconsistent results. [7][8][9][10][11][12][13][14][15][16][17][18][19] Some did report higher rates of complications, while others have reported that PD in this patient population is well tolerated, with no difference in technique difficulty. Furthermore, some observational data suggested that the prognosis of ADPKD patients on PD may appear to be better than, or at least equivalent to, ADPKD patients on HD 5,20 as well as those with other aetiologies of ESRD on PD.…”

mentioning

confidence: 99%

Outcomes of patients with autosomal‐dominant polycystic kidney disease on peritoneal dialysis: A meta‐analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

Dialysis modality and mortality in polycystic kidney disease

Abstract: There are no significant differences of mortality and survival between different dialysis modalities in PKD. PD may be as successful as HD for PKD patients receiving renal replacement therapy.

Cited by 8 publications

References 17 publications

Interleukin‐6 levels can be used to estimate cardiovascular and all‐cause mortality risk in dialysis patients: A meta‐analysis and a systematic review

Interleukin‐6 levels can be used to estimate cardiovascular and all‐cause mortality risk in dialysis patients: A meta‐analysis and a systematic review

Patients’ outcome with polycystic kidney disease firstly treated with peritoneal dialysis. Experience of our home dialysis unit since 1997.

Outcomes of patients with autosomal‐dominant polycystic kidney disease on peritoneal dialysis: A meta‐analysis

Contact Info

Product

Resources

About